Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 8/20 | 0.37 |
| ▸ | DHODH | Q02127 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462754 | 0.83 | P2RX7 (0.41) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL5762275 | 0.82 | KDM4E (0.43) | P2RX7ABCB11THRBALDH1A1HPGD | |
| SCHEMBL6462050 | 0.81 | P2RX7 (0.41) | P2RX7ABCB11THRBALDH1A1THRA | |
| SCHEMBL6453803 | 0.80 | P2RX7 (0.39) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL6459898 | 0.80 | THRB (0.39) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL6455333 | 0.79 | P2RX7 (0.42) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL5758791 | 0.79 | P2RX7 (0.40) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL6454146 | 0.79 | THRB (0.36) | P2RX7ABCB11THRBALDH1A1THRA | |
| SCHEMBL7142482 | 0.79 | P2RX7 (0.38) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL6459744 | 0.78 | MEN1 (0.39) | P2RX7ABCB11THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206471-B1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-01 | — | — | EP | disclosed |
| US-6911444-B2 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICS N.V. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1206471-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001010866-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | P2RX7 545/4885ABCB11 2943/4885THRB 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.